Drug intelligence / Profile preview

NG-049

Development stage: Preclinical
Lead developer: N-Gene Research Laboratories
Modality: Small Molecules

Overview

NG-049 is an investigational drug candidate developed by N-Gene Research Laboratories for the treatment of gastroesophageal reflux disease (GERD). It is part of N-Gene's pipeline of compounds, which historically focuses on the modulation of heat shock proteins (HSPs) and the inhibition of poly(ADP-ribose) polymerase (PARP). However, specific pharmacological data, including its exact molecular target and mechanism of action, have not been publicly disclosed. The development status of NG-049 is currently listed as 'pending,' indicating it is in the early research or preclinical stages.

Beyond the preview

Go deeper on NG-049.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NG-049.

Explore the full profile